Eric Winer, MD, wins prestigious 2017 Gianni Bonadonna Breast Cancer Award at ASCO

Posted date

Eric Winer, MD, has been presented with the 2017 Gianni Bonadonna Breast Cancer Award in recognition of his significant contributions to clinical and translational breast cancer research.  The award was given to Winer, Chief of Breast Oncology Center at the Susan F. Smith Center for Women’s Cancers and the Thompson Chair in Breast Cancer Research at Dana-Farber, by the American Society of Clinical Oncology’s (ASCO) at their Annual Meeting. 

First given in 2007, the Gianni Bonadonna award recognizes an active breast cancer researcher with a distinguished record of accomplishments in advancing the field of breast cancer and with exceptional mentoring abilities.

Throughout his career, Winer has personally led or helped guide dozens of clinical trials. Among his most notable recent achievements was overseeing a study in which patients with early-stage HER2-positive breast cancer received a limited course of paclitaxel with trastuzumab. Compared to standard regimens, there was far less toxicity, and the risk of disease recurrence remained exceedingly low. That treatment became a standard for stage I breast cancer around the world over the past couple of years

Dr. Winer is most proud, however, of the groups of investigators and clinicians he has been able to mentor at Dana-Farber over the last 2 decades. These individuals have since established independent research careers and thriving clinical practices that have had a major impact on patients with breast cancer.

The Gianni Bonadonna Breast Cancer Award will allow him to continue in that tradition. The award provides funding to a fellow in the amount of $50,000 which Winer will give to Dana-Farber’s, Ana Garrido-Castro, MD. The funds will support Garrido-Castro’s study of the genomic landscape of patients with triple negative breast cancer with residual disease after neoadjuvant chemotherapy.


News Category
Precision Cancer Medicine

Media Contacts

If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email media@dfci.harvard.edu.

The Media Team cannot respond to patient inquiries. For more information, please see Contact Us.